July 15, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2517588

Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease

Listen to this summary

The authors aimed to determine whether extending dual antiplatelet therapy (DAPT) beyond 12 months benefits event-free patients with multivessel coronary artery disease after stenting. In a randomized trial involving 8,250 patients, they found that extending DAPT reduced the risk of cardiovascular events compared to aspirin monotherapy, without increasing bleeding risks.

Jinwei Tian, Zhuozhong Wang, Yan Wang, Fan Wang, Xiang Peng, Jiandong Xiao, Chunjie Li, Xinyu Hou, Qian Tong, Xi Yu, Guangren Gao, Peng Zhao, Jie Zhao, Ying Liu, Zhexue Qin, Haijing Lu, Shujiang Zhang, Shengli Li, Zhiyuan Weng, Huifang Tang, Yuquan He, Chunpeng Zhang, Yong Liu, Jun Jiang, Jinying Zhang, Lei Cai, Lili Xiu, Gary S Mintz, Duolao Wang, Gregg W Stone, Bo Yu, DAPT-MVD Trial Investigators

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play